Form 4: Apellis General Counsel Sells Shares Under 10b5-1 Plan

Apellis Pharmaceuticals General Counsel David O. Watson sold 5,000 shares of common stock for $24.34 per share as part of a pre-arranged 10b5-1 trading plan.

Summary

• David O. Watson, General Counsel and Director of Apellis Pharmaceuticals, Inc. (APLS), reported a sale of common stock.
• The transaction involved the disposition of 5,000 shares of Apellis common stock.
• The shares were sold at a price of $24.34 per share.
• The total value of the transaction was $121,700.
• This sale was executed on September 16, 2025, pursuant to a Rule 10b5-1 trading plan established on March 3, 2025.
• Following the transaction, David O. Watson directly beneficially owns 118,730 shares of common stock.
• Additionally, 10,000 shares are indirectly owned through a custodial account for minor children, and 50,136 shares are indirectly owned through The David O. Watson Irrevocable Trust of 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's an insider sale, it was executed under a pre-arranged 10b5-1 plan, which suggests a planned financial management activity rather than a reaction to new company-specific information. The transaction size is also relatively small.

Positives

• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a structured and pre-scheduled approach to personal financial management rather than a reaction to new company developments.
• The filing demonstrates transparency in insider trading activities, adhering to SEC disclosure requirements.

Negatives

• An insider sale, even if planned, can sometimes be perceived by the market as a lack of confidence, although the 10b5-1 plan mitigates this interpretation.

Risks

• Potential for negative market sentiment if investors misinterpret the 10b5-1 sale as a signal of declining confidence, despite its pre-scheduled nature and relatively small size.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are a common practice in publicly traded companies. These plans allow insiders to sell a predetermined number of shares at a predetermined time or price, helping to avoid accusations of trading on material non-public information.

Related Party Transactions

• David O. Watson indirectly owns 10,000 shares through a custodial account for his minor children.
• David O. Watson indirectly owns 50,136 shares through The David O. Watson Irrevocable Trust of 2023, for which William Zorn is the trustee. The reporting person disclaims beneficial ownership over these shares except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders may note the insider sale, but given it's a pre-planned 10b5-1 transaction and a relatively small amount, the direct impact on shareholder confidence or company strategy is likely minimal.

Key Dates

Recommendation

The reported transaction is a routine insider sale executed under a pre-arranged 10b5-1 trading plan. This type of transaction is generally not indicative of a change in the company's fundamental outlook or the insider's confidence. The relatively small size of the sale ($121,700) for a company of Apellis's market capitalization further suggests it's unlikely to be a significant market signal. Therefore, this filing alone does not provide sufficient new information to warrant a change from a 'hold' recommendation.

Keywords

Apellis Pharmaceuticals, APLS, insider trading, Form 4, stock sale, David Watson, General Counsel, 10b5-1 plan